October 9, 2026 · Patent expires December 22, 2036

Ingrezza (valbenazine): The 2036-2038 Generic Opportunity Window

Neurocrine Biosciences' highly selective VMAT2 inhibitor for tardive dyskinesia and Huntington's chorea. Generated .51B in 2025 sales. Core patents expire late 2036; Hatch-Waxman settlements with generic filers (Lupin, Zydus) permit generic market entry on March 1, 2038. Currently 100% brand-only in the United States.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.